UK Medical Research Council and Albert Einstein College of Medicine technologies augment the company’s in-house development.
Anaptys Biosciences obtained exclusive licenses to complementary somatic hypermutation technologies from the UK Medical Research Council (MRC) and the Albert Einstein College of Medicine of Yeshiva University (AECOM). Somatic hypermutation is the natural process our bodies use for generating antibody diversity to fight disease.
Anaptys says its Omnitope-SHM™ System utilizes the key components of somatic hypermutation to enable the rapid variation and functional selection of evolved proteins with enhanced bioactivities.
“The MRC and AECOM technologies augment Anaptys’ in-house development of proprietary vectors and methods for creating antibodies and other proteins,” says William Boyle, Ph.D., co-founder, president and CSO of Anaptys. “With our Omnitope-SHM System, we can tap into the sequence variations brought about by SHM to rapidly and efficiently discover and optimize antibodies for a diverse set of disease targets.”
